Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company's focus ...

Modern Litho, a leading full-service publication and commercial printer, today announces a significant expansion of its direct mail capabilities at its St. Louis location. The company has recently ...

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share ...

Investors in Edgewise Therapeutics Inc (Symbol: EWTX) saw new options become available today, for the December 19th expiration. One of the key inputs that goes into the price an option buyer is ...

Many of his subjects were fashionable, bourgeois women, whom he depicted in an array of settings that reflected the many facets of modern life in the late 19th century. In brightly colored ...

An archive of scores by composer Arnold Schoenberg and the collections of countless contemporary artists have been lost in the blaze Sonja Anderson Daily Correspondent The wildfires still burning ...

Highlights so far of the 2025 contemporary dance festival, spread across New York City, are Symara Sarai and Leslie Cuyjet’s outstanding dances. By Gia Kourlas Symara Sarai, like a hurricane ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

January 13, 2025--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief ...

--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025.